Concurrent Investment Advisors LLC Sells 398 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Concurrent Investment Advisors LLC cut its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 29,719 shares of the biopharmaceutical company’s stock after selling 398 shares during the quarter. Concurrent Investment Advisors LLC’s holdings in Gilead Sciences were worth $2,745,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of the company. Avior Wealth Management LLC increased its position in shares of Gilead Sciences by 1.2% during the 3rd quarter. Avior Wealth Management LLC now owns 9,422 shares of the biopharmaceutical company’s stock valued at $782,000 after purchasing an additional 108 shares during the last quarter. Southland Equity Partners LLC increased its position in shares of Gilead Sciences by 3.6% during the 4th quarter. Southland Equity Partners LLC now owns 3,128 shares of the biopharmaceutical company’s stock valued at $289,000 after purchasing an additional 110 shares during the last quarter. Concord Asset Management LLC VA increased its position in shares of Gilead Sciences by 3.8% during the 3rd quarter. Concord Asset Management LLC VA now owns 3,056 shares of the biopharmaceutical company’s stock valued at $256,000 after purchasing an additional 111 shares during the last quarter. Berkshire Bank increased its position in shares of Gilead Sciences by 3.4% during the 4th quarter. Berkshire Bank now owns 3,398 shares of the biopharmaceutical company’s stock valued at $314,000 after purchasing an additional 111 shares during the last quarter. Finally, TFB Advisors LLC increased its position in shares of Gilead Sciences by 1.2% during the 3rd quarter. TFB Advisors LLC now owns 9,397 shares of the biopharmaceutical company’s stock valued at $788,000 after purchasing an additional 116 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, Director Jeffrey Bluestone sold 6,788 shares of the business’s stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total value of $620,355.32. Following the completion of the transaction, the director now owns 8,920 shares in the company, valued at $815,198.80. The trade was a 43.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $104.09, for a total value of $260,225.00. Following the completion of the transaction, the chief financial officer now owns 169,061 shares of the company’s stock, valued at $17,597,559.49. This represents a 1.46 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 713,000 shares of company stock valued at $67,945,181. 0.16% of the stock is currently owned by corporate insiders.

Gilead Sciences Trading Down 0.1 %

NASDAQ GILD opened at $109.95 on Friday. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $111.03. The firm has a market capitalization of $137.03 billion, a PE ratio of 297.16, a P/E/G ratio of 0.90 and a beta of 0.18. The stock’s 50 day moving average is $95.41 and its 200 day moving average is $88.63.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. Research analysts forecast that Gilead Sciences, Inc. will post 7.94 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be issued a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 2.87%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date of this dividend is Friday, March 14th. Gilead Sciences’s payout ratio is 832.43%.

Analysts Set New Price Targets

GILD has been the topic of a number of analyst reports. Piper Sandler lifted their price target on Gilead Sciences from $105.00 to $110.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 12th. Barclays lifted their price target on Gilead Sciences from $84.00 to $95.00 and gave the stock an “equal weight” rating in a research note on Thursday, November 7th. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a research note on Wednesday, February 12th. Oppenheimer lifted their price target on Gilead Sciences from $105.00 to $115.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 10th. Finally, Royal Bank of Canada lifted their price target on Gilead Sciences from $84.00 to $90.00 and gave the stock a “sector perform” rating in a research note on Wednesday, February 12th. Eleven research analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $102.08.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.